Renaissance Technologies LLC Increases Stake in LivaNova PLC (NASDAQ:LIVN)

Renaissance Technologies LLC grew its stake in LivaNova PLC (NASDAQ:LIVN - Free Report) by 9.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 112,594 shares of the company's stock after buying an additional 9,500 shares during the period. Renaissance Technologies LLC owned 0.21% of LivaNova worth $5,214,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of LIVN. Geode Capital Management LLC boosted its stake in LivaNova by 0.6% in the third quarter. Geode Capital Management LLC now owns 1,344,949 shares of the company's stock valued at $70,676,000 after acquiring an additional 8,331 shares in the last quarter. Sanctuary Advisors LLC purchased a new stake in LivaNova in the third quarter valued at approximately $219,000. Central Pacific Bank Trust Division increased its stake in LivaNova by 21.2% in the fourth quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company's stock valued at $191,000 after purchasing an additional 720 shares during the period. Nordea Investment Management AB lifted its position in LivaNova by 22.2% during the 4th quarter. Nordea Investment Management AB now owns 68,711 shares of the company's stock worth $3,188,000 after acquiring an additional 12,470 shares during the period. Finally, Diversified Trust Co grew its stake in shares of LivaNova by 9.5% in the 4th quarter. Diversified Trust Co now owns 16,432 shares of the company's stock valued at $761,000 after purchasing an additional 1,425 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on LIVN shares. Wolfe Research downgraded shares of LivaNova from an "outperform" rating to a "peer perform" rating in a research report on Wednesday, February 26th. StockNews.com raised LivaNova from a "buy" rating to a "strong-buy" rating in a report on Tuesday, March 25th. Barclays dropped their price objective on LivaNova from $58.00 to $56.00 and set an "equal weight" rating on the stock in a report on Friday, March 7th. Needham & Company LLC restated a "buy" rating and set a $64.00 target price on shares of LivaNova in a research report on Monday, March 17th. Finally, Mizuho reduced their price objective on shares of LivaNova from $70.00 to $60.00 and set an "outperform" rating for the company in a research note on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $61.17.

LivaNova Price Performance

Shares of LIVN stock traded down $0.44 during trading hours on Friday, hitting $36.83. The company's stock had a trading volume of 142,541 shares, compared to its average volume of 621,974. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. LivaNova PLC has a twelve month low of $32.48 and a twelve month high of $64.48. The stock has a market cap of $2.00 billion, a price-to-earnings ratio of 87.70 and a beta of 0.90. The business has a fifty day moving average of $39.14 and a 200-day moving average of $46.28.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.